Live market screen
Commercial Space Company Risk / Opportunity Ranking
Opportunity/risk view across launch, satellites, SAR, earth observation, defense demand, financing events, and execution risk.
Updated June 27, 2026
Opportunity view
Showing rows 141-160 of 438; 20 rows per page.
| Rank | Company | Score | Thesis / Evidence |
|---|---|---|---|
| 141 | Muon Space lowweak | Opp 3 Risk 3 | Thesis: Muon Space has some long-horizon optionality because the reviewed sources context places it in satellite constellations and atmospheric/ocean/land measurement, suggesting a real operating footprint in an attractive segment. Why now: The most recent dated context is a May 22, 2026 job posting indicating contracting and legal operations needs, which may imply organizational buildout but is weak evidence for a major catalyst. Evidence
Caveats: The reviewed sources contain no direct positive or negative company-specific events. The May 22, 2026 job posting is operational context, not proof of revenue or contracts. Citation |
| 142 | NordSpace Corp. lowweak | Opp 3 Risk 3 | Thesis: Reviewed evidence context identifies NordSpace as one of three Canadian rocket startups awarded government funding, which is a constructive signal for a long-horizon launch-company buildout, but there is no available in-window evidence to assess amount, timing, milestones, or commercialization follow-through. Why now: The only directional clue is the membership-support article reference: but the reviewed sources includes no, no summary, and no available post-recent evidence window evidence, so timing and durability are uncertain. Caveats: No direct evidence available after recent evidence window for this company. Membership rationale references article ID: but the reviewed sources provide no or article summary. Opportunity case relies on generic funding support mention without current milestone evidence. |
| 143 | Orbit Fab lowweak | Opp 3 Risk 2 | Thesis: Orbit Fab appears strategically interesting in on-orbit refueling and space logistics. The company website summary describes 'In-Space Fuel Delivery,' RAFTI refueling interfaces, and 'Hydrazine Delivery in GEO for 100kg. Available in 2025,' which would matter over a 1 year+ horizon if still current, but that article is dated December 24, 2022 and outside the 90-day recent evidence window, so it is only weak historical context. Within retained evidence, an undated external list says Orbit Fab is 'operating' in in-orbit servicing, which supports relevance but not a strong near-current thesis. Why now: Why now is only moderate because retained evidence after filtering consists of undated context from Space Index, not a dated current catalyst; the older company-site article from December 24, 2022 may indicate strategic readiness, but recency is weak Evidence
Caveats: Retained evidence is weak context and supporting article context, not direct event/fact evidence. The more detailed article is dated December 24, 2022 and was dropped by the 90-day recent evidence window; it should not be treated as current proof. The undated Space Index row is relevance context only and not recency proof. |
| 144 | OrbitAID Aerospace lowweak | Opp 3 Risk 2 | Thesis: OrbitAID appears positioned in on-orbit refueling, docking, repair, inspection, and life-extension services, which could be strategically attractive over a 1 year+ horizon if execution follows, but the reviewed sources only provides undated article-level company context rather than dated wins, funding, customers, or milestones. Why now: Why now is weak because the surviving evidence is undated company-context material rather than a fresh milestone. Recency-sensitive claims are uncertain Evidence
Caveats: Evidence kept after recent evidence window is undated and marked context, not recency proof. No direct positive event, contract, financing, or customer traction is available. Same-article repeated rows are not independent confirmation. |
| 145 | Orbital lowweak | Opp 3 Risk 2 | Thesis: Among this screen, Orbital has one of the clearer positive reviewed sources rationales: it is described as a private space startup with funding and a planned LEO satellite for orbital data centers, which suggests longer-horizon strategic buildout potential if execution continues, and, no provided in reviewed sources). Why now: The only reason to rank it slightly above peers is the reviewed sources' description of funding plus a planned LEO satellite, which is at least directionally aligned with a 1 year+ horizon. But there is no retained dated evidence to verify recency, sequencing, or milestone timing. Caveats: No are provided for the cited support articles in the reviewed sources. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. The positive view comes from phase2 rationale text rather than available direct event/facts. |
| 146 | Orbital Recovery Crew lowweak | Opp 3 Risk 3 | Thesis: Orbital Recovery Crew presents a speculative long-horizon opportunity because recent website-level context claims it provides end-to-end retrieval, repositioning, and deorbit services across LEO, MEO, and GEO and is 'Licensed. Insured. Operational since 2011,' which, if accurate, implies operational positioning in on-orbit servicing and debris removal. Why now: The only retained evidence is a page with May 21, 2026, within the 90-day window, indicating recent discoverable claims of operations and service scope, but not a third-party validated catalyst. Evidence
Caveats: Evidence is company-site article context, not independent confirmation. No direct positive or negative dated events are available. Same-article repeated rows are not independent confirmation. |
| 147 | Planet Labs PBC lowweak | Opp 3 Risk 3 | Thesis: Planet Labs is clearly relevant as a satellite constellation and geospatial data company, but the reviewed sources only provides generic article-level business description rather than a dated catalyst or company-specific contract milestone. Why now: Why-now is weak: the only in-window evidence is an April 5, 2026 startup-listing article describing Planet as operating its own satellite constellation and geospatial analytics platform, which is durable context but not a clear catalyst. Evidence
Caveats: Evidence is only supporting article context, not direct company event or fact evidence with strong materiality. No direct positive or negative dated events are available. This is a low-conviction watchlist name in these reviewed sources. |
| 148 | Reaction Dynamics lowweak | Opp 3 Risk 3 | Thesis: Reviewed evidence rationale identifies Reaction Dynamics as one of three Canadian rocket startups awarded government funding. Government support can be a meaningful de-risking signal for a 1 year+ development runway if still current. Why now: The support is tied to article: in the membership rationale, which suggests a relatively recent funding-related development, but the active evidence set still contains zero available rows after recent evidence filtering. Caveats: Government funding mention is promising but unquantified in the active evidence set. No chronology-confirmed operational updates are available. |
| 149 | Sierra Nevada Corporation lowweak | Opp 3 Risk 3 | Thesis: Among this screen, Sierra Nevada Corporation has one of the more plausible long-horizon opportunity setups because the reviewed sources rationale says SNC has a small satellite constellation, Vindler 2.0, and on-orbit RF data transmission activity, which could indicate real space-communications or constellation relevance if validated. Why now: If the referenced constellation and on-orbit transmission activity are current, they could matter over a 1 year+ horizon; however, the reviewed sources provide no available after-recent evidence window evidence to confirm recency or milestone sequence. Caveats: Phase-2 rationale references: and: but no or article summaries are included. The reviewed sources explicitly warns that the evidence mixes SNC and Sierra Space-adjacent themes. Coverage debug shows zero evidence after recent evidence window, so direct validation is unavailable. |
| 150 | SKY Perfect JSAT lowweak | Opp 3 Risk 2 | Thesis: An undated supporting article context item says Astroscale and SKY Perfect JSAT formed a strategic partnership on on-orbit servicing and that the partnership includes an investment by SKY Perfect JSAT, which could support strategic optionality in adjacent space services if current Why now: This is one of the only companies in the screen with any current evidence surviving the recent evidence window, but it is undated supporting context, so why-now confidence is still limited Evidence
Caveats: Evidence is undated and supporting article context only. Same article appears in multiple weak-context rows and is not independent confirmation. No direct positive event/fact beyond supporting context. |
| 151 | Spacecoin lowweak | Opp 3 Risk 3 | Thesis: Spacecoin may have speculative upside over a 1 year+ horizon because the reviewed sources describes it as a private blockchain startup using satellite-based transactions and aiming at a decentralized satellite network, which could represent an emerging infrastructure concept if execution materializes. Why now: If the network concept is advancing, that could be relevant over a long horizon, but the reviewed sources offers no available recency-validated milestone evidence after recent evidence window. Caveats: Phase-2 rationale references and, but no or summaries are included. Business-model adjacency to satellite communications is not the same as proven operating traction. Coverage debug shows zero evidence after recent evidence window. |
| 152 | Spaceflux lowweak | Opp 3 Risk 1 | Thesis: Spaceflux has a plausible long-horizon opportunity setup because the reviewed sources' membership rationale says it received a £100K follow-on investment through a UK space funding program and notes relevance to debris tracking. That can support an SDA-adjacent thesis, but the reviewed sources lack direct positive evidence and gives no or dated article detail to confirm magnitude or timing (: not provided in reviewed sources). Why now: A follow-on investment could matter over 1 year+ if it extends development in debris tracking, but there is no available dated evidence within the recent evidence window and no direct article summary/ in the reviewed sources. Caveats: Only article-level rationale is available. Funding size may be modest, but reviewed sources does not provide enough context to judge materiality precisely. No representative article or quote available. |
| 153 | SWISSto12 lowweak | Opp 3 Risk 2 | Thesis: The reviewed sources membership rationale describes SWISSto12 as delivering HummingSat GEO telecom platforms and NEASTAR-1 direct-to-device media broadcasting capability, which, if current, suggests exposure to durable satellite communications platform programs over a 1 year+ horizon. Why now: There is no dated evidence retained after recent evidence window for SWISSto12. Coverage debug shows zero article IDs after recent evidence window and zero evidence after recent evidence window, so the timing case is not established from these reviewed sources. Caveats: Assessment relies only on the reviewed sources' membership rationale, not direct quoted event/fact evidence with support. No representative articles are included despite article IDs being referenced in the rationale. Potential opportunity could be meaningful, but evidentiary support inside these reviewed sources is too thin for a stronger score. |
| 154 | TM2SPACE Technologies lowweak | Opp 3 Risk 4 | Thesis: TM2SPACE may have opportunity from reported selection for IN-SPACe funding under the Technology Adoption Fund for AI-powered star tracker systems, but the reviewed sources does not include the underlying article summaries or evidence in the served evidence section. Why now: The membership rationale references selection for IN-SPACe funding and AI-powered star tracker work using article IDs, and: but no article summaries, or direct evidence are available in these reviewed sources after recent evidence window, so recency and materiality cannot be independently verified from the evidence body. Caveats: No representative articles, or available evidence available to cite directly beyond membership rationale. Coverage debug shows zero article IDs after recent evidence window and zero evidence after recent evidence window. Scoring is conservative because reviewed sources support is incomplete in the visible evidence section. |
| 155 | True Anomaly Centennial lowweak | Opp 3 Risk 2 | Thesis: Reviewed evidence membership rationale says True Anomaly was included among 14 vendors selected by the U.S. Space Force for space monitoring satellites under the Andromeda program. If current, that implies meaningful government-program relevance over a 1-year-plus horizon, but the reviewed sources lack citeable direct evidence or. Why now: Government program selection could matter over 1 year+, but the reviewed sources does not provide surviving evidence with timing details after recent evidence window. Caveats: No -bearing direct evidence row is available for the referenced Andromeda selection article. Selection does not prove revenue realization or contract scale. |
| 156 | Turion Space lowweak | Opp 3 Risk 3 | Thesis: Turion Space may have an attractive defense and space-monitoring positioning based on the membership rationale mentioning fundraising, U.S. government contracts, STRATFI launches, and Andromeda selection, but the reviewed sources includes no within the recent evidence window evidence or article summaries to support a high-conviction opportunity ranking. Why now: No within the recent evidence window evidence was available in these reviewed sources, so the timing case is weak despite the strategic framing in the membership rationale. Caveats: Membership rationale references article IDs and, but no article content is provided here for citation. Evidence recent evidence review shows 0 kept rows. Scores remain conservative because the reviewed sources lack usable direct evidence. |
| 157 | Vast, Inc. lowweak | Opp 3 Risk 3 | Thesis: Reviewed evidence rationale says Vast raised $500M and is building Haven commercial space stations and related habitats, which would be material long-duration opportunity if current, but these reviewed sources contain no within the recent evidence window direct evidence or representative article summaries to support a stronger score. Why now: Why-now is unproven from these reviewed sources because no dated evidence survived the 90-day recent evidence window despite 11 articles considered. Caveats: Phase2 membership rationale references and, but no summaries or evidence are available for citation. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Scores remain near low baseline due to absence of directly citable local evidence. |
| 158 | Voyager Technologies, Inc. lowweak | Opp 3 Risk 3 | Thesis: Reviewed evidence context says Voyager Technologies is developing the Starlab space station, which is strategically meaningful for a 1 year+ horizon if execution continues, but no direct in-window evidence is available to confirm current milestones, financing, contract conversion, or timetable. Why now: No current catalyst is evidenced in the reviewed sources. Although membership support references article IDs and, the reviewed sources show 0 article IDs after recent evidence window and 0 evidence after recent evidence window, so business-state recency cannot be established. Caveats: No direct evidence available after recent evidence window for this company. Membership rationale references article IDs and, but the reviewed sources provide no or article summaries for citation. |
| 159 | WISeKey International Holding AG lowweak | Opp 3 Risk 4 | Thesis: Reviewed evidence context indicates WISeKey, via WISeSat, is tied to a planned QSOC 100-satellite constellation with post-quantum satellite launches. If executed, that could matter over a 1 year+ horizon, but the reviewed sources provide no current in-window evidence confirming launch cadence, financing, customer uptake, or operational progress. Why now: There is no documented near-term catalyst in the available evidence. Membership support cites article IDs and, but the reviewed sources reports 0 article IDs after recent evidence window and 0 evidence after recent evidence window. Caveats: No direct evidence available after recent evidence window for this company. Membership rationale references article IDs and, but the reviewed sources does not include or article summaries for citation. Risk is inferred from lack of current execution proof, not from a confirmed adverse event. |
| 160 | Xona Space lowweak | Opp 3 Risk 2 | Thesis: Xona has potential strategic opportunity because the reviewed sources describes Pulsar as a low-Earth-orbit positioning, navigation, and timing infrastructure using 258 small satellites, implying an ambitious constellation and differentiated service if executed. Why now: Why now is weak: the only surviving evidence is undated, so recency-sensitive claims are uncertain Evidence
Caveats: Evidence is undated and should not be treated as recency proof. No direct positive event or traction evidence is available. Opportunity case is strategic but low-conviction. |
Risk view
Showing rows 41-60 of 438; 20 rows per page.
| Rank | Company | Score | Thesis / Evidence |
|---|---|---|---|
| 41 | PLD Space highstrong | Opp 8 Risk 4 | Thesis: Execution risk remains meaningful because the key value inflection still depends on MIURA 5 development and inaugural test-flight timing later in 2026 rather than already-proven orbital commercial cadence. Why now: The reviewed sources show a sequence of material developments: €180 million Series C on March 4, 2026, €30 million EIB venture debt signed April 7, 2026 and reported May 6, 2026/04-07, first commercial contract reported May 21, 2026, and €35 million Kourou launch-complex investment on June 1, 2026 while MIURA 5 remained on track for a late-2026 first test flight. That is strong state-change evidence for a 1 year+ horizon. Evidence
Caveats: Risk evidence is partly inferred from dependency on future launch milestones rather than a disclosed adverse event. Most support is supporting article context, though the chronology is consistent and material. |
| 42 | Rocket Lab USA, Inc. highstrong | Opp 7 Risk 4 | Thesis: Risk is moderate because the reviewed sources' key opportunity is still relatively early in size and scope compared with SpaceX, and execution must extend from launch into GEO satellite production and operation. Why now: The main catalyst is the May 2026 award of Rocket Lab's first GEO satellite production program for the U.S. Space Force, which extends the company into a new orbital regime and broadens its mission model. That is paired with evidence of ongoing launch execution on May 22, 2026 through the ninth dedicated Electron mission for Synspective. Evidence
Caveats: The reviewed sources contain no direct negative events, so risk is mainly execution-based rather than explicitly evidenced adverse news. One representative item references stock performance but is undated and should not be treated as reliable recency proof. |
| 43 | SatSure mediummedium | Opp 7 Risk 4 | Thesis: Risk remains meaningful because the reviewed sources classifies the available evidence mostly as weak supporting article context rather than direct positive events/facts, and there is no available direct evidence for commercial revenue conversion, deployment success, or execution milestones beyond the grant and partnership narratives Why now: Why now is strong because the June 11-22, 2026 evidence sequence shows fresh capital support first, then a later strategic partnership, suggesting opportunity maturation within weeks rather than stale background context Evidence
Caveats: Most evidence is supporting article context or weak context rather than direct positive events. Same-story repetition around the grant should not be treated as independent confirmation. No direct available evidence of revenue, backlog conversion, or deployment milestones. |
| 44 | Scout Space mediummedium | Opp 6 Risk 4 | Thesis: Risk remains meaningful because the reviewed sources' usable support is mostly supporting article context rather than direct positive events, and the financing is growth capital for a private company rather than proof of commercial conversion at scale. Why now: A dated May 6, 2026 article says Scout raised up to $18 million Series A and will use the capital for mission execution and expansion of manufacturing capabilities, creating a current capacity-building milestone for the next year, May 6, 2026). Evidence
Caveats: Most available support is weak context/supporting article context rather than direct positive events. Blue Origin partnership articles are from 2025 and were outside the 90-day recent evidence window, so they should not drive recency-based ranking |
| 45 | Skyroot Aerospace mediummedium | Opp 5 Risk 4 | Thesis: The main risk is launch execution risk because the reviewed sources frames Vikram-1 as a preparation-stage maiden orbital mission rather than an already completed orbital launch, and there is no additional direct evidence in the reviewed sources showing later de-risking. Why now: The relevant dated development is the reported financing on May 7, 2026 alongside the stated approach to the Vikram-1 maiden flight, which fits a 1 year+ thesis if execution progresses. Evidence
Caveats: Support is supporting article context only; the reviewed sources have no direct positive events available for Skyroot. Same-article repeated context rows are not independent confirmation. |
| 46 | SpaceX highstrong | Opp 9 Risk 4 | Thesis: Risk exists from concentration in large government programs and evidence of pricing tension with the Pentagon, but the reviewed sources does not show a material adverse operational or financial event inside the recent evidence window. Why now: The timing is supported by late-May 2026 contract awards: a $2.29 billion Space Force data-network award dated May 26, 2026 and a $4.16 billion Space Force SB-AMTI award dated May 29, 2026/May 30, 2026, plus NASA's plan dated May 24, 2026 to add missions to SpaceX's commercial crew contract, all of which indicate durable backlog expansion and franchise entrenchment over a 1 year+ horizon. Evidence
Caveats: The reviewed sources' available source fields contain no direct positive or negative events for SpaceX; opportunity is inferred from high-materiality neutral facts and article summaries. Ticker mapping is noisy in the reviewed sources: SpaceX is shown with ticker TSLA, which should not be treated as validated public-company identity here. |
| 47 | SpinLaunch lowweak | Opp 4 Risk 4 | Thesis: The same constellation-buildout framing also implies material execution risk because the reviewed sources provide no fresh in-window evidence confirming funding sufficiency, deployment timing, customer demand, or progress beyond the build statement. Why now: There is no direct, dated catalyst in the available evidence. The reviewed sources references article ID: for membership support, but provides no and shows 0 evidence after recent evidence window, so current status cannot be verified. Caveats: No direct evidence available after recent evidence window for this company. Membership rationale references article ID: but the reviewed sources does not include a or summary for citation. |
| 48 | Spire Global, Inc. lowweak | Opp 2 Risk 4 | Thesis: Risk is modestly higher than opportunity because there is effectively no fresh reviewed evidence to validate current traction, contracts, or program wins after the March 29, 2026 cutoff. The issue is not reviewed sources-proven deterioration, but lack of current support. Why now: There is no current catalyst in the kept ranking evidence. The only representative article provided is dated February 7, 2025, outside the recent evidence window, via at Caveats: Zero evidence were kept after the 90-day recent evidence window. The available article context is outside recent evidence window and should not be treated as current catalyst evidence. |
| 49 | Starcloud mediummedium | Opp 6 Risk 4 | Thesis: Starcloud also carries meaningful execution risk because the reviewed sources evidence frames the business around an extremely ambitious proposed constellation scale and supporting article context rather than direct company events. The May 26, 2026 article says the constellation ultimately envisions 88,000 orbital data centers, a very large scope that implies substantial execution and capital intensity risk. Why now: Within the 90-day recent evidence window, Starcloud has the clearest sequence of dated business-state updates: funding on March 30, 2026, network-equipment contract on May 26, 2026, and additional context on capital raised and market positioning on June 10, 2026, For a 1 year+ horizon, that sequence supports an active buildout story even though evidence quality is not fully direct. Evidence
Caveats: All usable evidence is supporting article context; the reviewed sources provide no direct positive or negative dated event/facts. Repeated Starcloud claims across articles are not independent confirmation under the evidence standard. Opportunity and risk both remain dependent on future execution over a long horizon. |
| 50 | Stellar Alpina AG lowweak | Opp 5 Risk 4 | Thesis: The same rationale also implies significant technology and commercialization risk: pre-seed stage, advanced propulsion development, and no available proof of contracts, flight validation, or revenue traction in the reviewed sources. Why now: Why now is relatively better than peers because the rationale includes a recent capital raise and a specific product focus, both of which can influence a 1 year+ strategic trajectory, though no direct dated evidence are available to verify recency sequencing. Caveats: Membership rationale cites article IDs: and: but no are present. The reviewed sources contain no direct positive or negative evidence arrays despite the financing statement in the rationale. Early-stage propulsion development is inherently high-uncertainty, but that is inferred from stage and product type, not from a available adverse article. |
| 51 | TM2SPACE Technologies lowweak | Opp 3 Risk 4 | Thesis: Risk is modest because there is too little available evidence after recent evidence window to support a stronger positive or negative view, making outcome uncertainty high. Why now: The membership rationale references selection for IN-SPACe funding and AI-powered star tracker work using article IDs, and: but no article summaries, or direct evidence are available in these reviewed sources after recent evidence window, so recency and materiality cannot be independently verified from the evidence body. Caveats: No representative articles, or available evidence available to cite directly beyond membership rationale. Coverage debug shows zero article IDs after recent evidence window and zero evidence after recent evidence window. Scoring is conservative because reviewed sources support is incomplete in the visible evidence section. |
| 52 | Tomorrow.io lowweak | Opp 5 Risk 4 | Thesis: Risk remains meaningful because the reviewed sources provide only thin support beyond the financing statement; there is no available kept direct positive event detail, customer traction, deployment milestone, or contract evidence to validate execution progress. Why now: The 'why now' is the capital raise described in the reviewed sources' membership rationale via article: but the ranking payload does not include the article or a richer reviewed evidence row, so recency and detail are only partially grounded. Evidence
Caveats: The reviewed sources does not provide the article for the cited membership-support article. This is mainly a financing-backed opportunity thesis, not a contract- or revenue-backed one in these reviewed sources. |
| 53 | Transcelestial lowweak | Opp 5 Risk 4 | Thesis: Risk is moderately elevated because, despite the promising rationale, the reviewed sources show no representative article details, no direct positive evidence, and zero article IDs after recent evidence window in coverage debug. That creates substantial verification and timing uncertainty. Why now: Why now is only moderate because the membership rationale references support references including, and: but the reviewed sources does not provide or article summaries for them. Without visible dated article detail, the near-current business state cannot be confirmed. Caveats: Important claims appear only in the membership rationale; no -bearing direct evidence is exposed. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. |
| 54 | True Anomaly highstrong | Opp 8 Risk 4 | Thesis: Risk remains meaningful because the company is tied to a demanding defense-space interceptor effort, and one source notes $50 million of the financing was debt, which adds some balance-sheet/obligation risk. In addition, much of the evidence comes from external articles and company-associated announcements rather than a broader set of independently available direct events. Why now: The recent sequence matters: on April 28, 2026, True Anomaly announced a $650 million Series D at a $2.2 billion valuation, also. Then on May 4, 2026, a dated article said the company was selected by the U.S. Space Force Space Systems Command for the Space-Based Interceptor program. That capital-plus-program sequence is directly relevant to a long-horizon growth thesis. Evidence
Caveats: Most evidence is external overlay context/facts rather than primary data source direct events. Several sources repeat the same April 28 financing story and are not independent confirmation of different events. The company-site article is undated, so recency-sensitive claims from it should be treated cautiously. |
| 55 | Unastella lowweak | Opp 5 Risk 4 | Thesis: Even with the stated Series B and launch success, launch-vehicle companies remain execution- and capital-intensive, and the reviewed sources provide no available evidence on follow-on contracts, cadence, or economics. Risk is therefore still elevated. Why now: Why now is relatively stronger because the rationale includes both funding and a technical milestone, which are durable indicators for a 1 year+ horizon, though exact dates and chronology cannot be checked from the reviewed sources' empty post-recent evidence window evidence tables. Caveats: Membership rationale cites article IDs: and: but no are given. No direct events or summaries are available after recent evidence window, so success claims cannot be quoted from the reviewed sources. Opportunity and risk both reflect a capital-intensive launch model with limited reviewed sources verification. |
| 56 | Univity lowweak | Opp 5 Risk 4 | Thesis: The same evidence implies meaningful execution risk: building a satellite network is capital intensive and ambitious, while the reviewed sources offers only one supporting article and no direct follow-on customer, launch, or technical milestone evidence. Why now: Why now is the claimed funding event and network build plan referenced in article ID: but the reviewed sources does not provide the article or detailed timestamp, so recency is only partially grounded. Caveats: The key claim comes from membership rationale rather than available direct evidence. Article ID: is referenced without a. No evidence of downstream execution, contracts, launches, or adoption is present. |
| 57 | Vantor lowweak | Opp 5 Risk 4 | Thesis: Risk is elevated because the reviewed sources does not expose the underlying article summaries or -bearing evidence for those contract claims inside the ranking section, and coverage debug shows zero article IDs after recent evidence window and zero evidence available after recent evidence window. That leaves execution and verification risk high. Why now: Why now is only moderate because the membership rationale references significant contracts via support references including: but the reviewed sources provide no or representative article detail for citation-quality corroboration. The forecast horizon of 1 year+ could fit contract conversion and constellation expansion if current, but recency cannot be validated from visible article rows. Caveats: The contract and expansion claims appear only in membership rationale text; no representative article with is included. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. |
| 58 | Vast Space mediummedium | Opp 6 Risk 4 | Thesis: Risk remains elevated because the same body of context portrays Vast as pursuing multiple capital-intensive initiatives at once—commercial space stations, NASA contract competition, and now satellite manufacturing. Earlier dated March items about a $500 million raise were outside the recent evidence window and therefore cannot be primary support here, so the retained case still relies on supporting article context rather than direct event/facts, leaving execution and commercialization risk significant, May 19, 2026, May 19, 2026). Why now: The timing case is stronger than peers because the product expansion articles are dated May 19, 2026 and May 20, 2026, within the 90-day recent evidence window, and represent a potentially durable strategic change: moving into satellite buses rather than remaining only a station developer, May 19, 2026, May 20, 2026). Evidence
Caveats: Retained evidence is weak context supporting article context; there are no direct positive event/facts available. The March 2026 financing articles are outside the 90-day recent evidence window and cannot be primary support, even though they appear in representative articles. Several retained rows summarize the same basic product announcement and should not be treated as independent confirmation. |
| 59 | WISeKey International Holding AG lowweak | Opp 3 Risk 4 | Thesis: Execution risk appears elevated because the thesis depends on a planned constellation and post-quantum satellite rollout, yet the reviewed sources lack fresh evidence validating current status. With no direct negative event available, the risk score is driven by uncertainty around plan-to-execution conversion rather than confirmed deterioration. Why now: There is no documented near-term catalyst in the available evidence. Membership support cites article IDs and, but the reviewed sources reports 0 article IDs after recent evidence window and 0 evidence after recent evidence window. Caveats: No direct evidence available after recent evidence window for this company. Membership rationale references article IDs and, but the reviewed sources does not include or article summaries for citation. Risk is inferred from lack of current execution proof, not from a confirmed adverse event. |
| 60 | Wyvern lowweak | Opp 4 Risk 4 | Thesis: Risk is moderate because the available evidence is undated supporting article context from the company site. Since the basis is explicitly 'undated,' recency-sensitive claims about current constellation readiness, capacity, and commercial position are uncertain. Why now: Why now is weak because the evidence retained is undated and the reviewed sources explicitly says to treat recency-sensitive claims cautiously when no is available. The underlying strategic area may be attractive, but current business-state confirmation is missing. Evidence
Caveats: Evidence is undated, so current-state claims are less reliable for timing judgments. Only supporting article context is provided, not direct event evidence. No direct customer, contract, financing, or negative-event evidence is shown. |